nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—Protein Kinase Inhibitors—Sunitinib—pancreatic cancer	0.551	1	CiPCiCtD
Nilotinib—MAP4K1—Sunitinib—pancreatic cancer	0.0248	0.0865	CbGbCtD
Nilotinib—EPHA6—Erlotinib—pancreatic cancer	0.0241	0.0839	CbGbCtD
Nilotinib—ABL2—Erlotinib—pancreatic cancer	0.0216	0.0754	CbGbCtD
Nilotinib—MAP2K5—Erlotinib—pancreatic cancer	0.0197	0.0687	CbGbCtD
Nilotinib—FGR—Sunitinib—pancreatic cancer	0.0179	0.0626	CbGbCtD
Nilotinib—BLK—Sunitinib—pancreatic cancer	0.0159	0.0553	CbGbCtD
Nilotinib—EPHB6—Sunitinib—pancreatic cancer	0.0159	0.0553	CbGbCtD
Nilotinib—ABL1—Erlotinib—pancreatic cancer	0.0156	0.0545	CbGbCtD
Nilotinib—PDGFRA—Sunitinib—pancreatic cancer	0.0142	0.0497	CbGbCtD
Nilotinib—CSF1R—Sunitinib—pancreatic cancer	0.0142	0.0497	CbGbCtD
Nilotinib—KIT—Sunitinib—pancreatic cancer	0.0142	0.0497	CbGbCtD
Nilotinib—PDGFRB—Sunitinib—pancreatic cancer	0.013	0.0452	CbGbCtD
Nilotinib—MAP2K5—Sunitinib—pancreatic cancer	0.013	0.0452	CbGbCtD
Nilotinib—UGT1A1—Erlotinib—pancreatic cancer	0.00649	0.0226	CbGbCtD
Nilotinib—UGT1A1—Irinotecan—pancreatic cancer	0.00586	0.0205	CbGbCtD
Nilotinib—ABCG2—Tamoxifen—pancreatic cancer	0.0042	0.0147	CbGbCtD
Nilotinib—ABCG2—Erlotinib—pancreatic cancer	0.00357	0.0125	CbGbCtD
Nilotinib—ABCG2—Irinotecan—pancreatic cancer	0.00323	0.0112	CbGbCtD
Nilotinib—ABCG2—Fluorouracil—pancreatic cancer	0.0031	0.0108	CbGbCtD
Nilotinib—CYP2B6—Tamoxifen—pancreatic cancer	0.00295	0.0103	CbGbCtD
Nilotinib—ABCG2—Docetaxel—pancreatic cancer	0.00236	0.00824	CbGbCtD
Nilotinib—ABCG2—Sunitinib—pancreatic cancer	0.00235	0.00821	CbGbCtD
Nilotinib—CYP2B6—Irinotecan—pancreatic cancer	0.00227	0.00791	CbGbCtD
Nilotinib—CYP2C8—Tamoxifen—pancreatic cancer	0.00224	0.0078	CbGbCtD
Nilotinib—CYP2C8—Erlotinib—pancreatic cancer	0.0019	0.00664	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—pancreatic cancer	0.00176	0.00615	CbGbCtD
Nilotinib—CYP2C8—Fluorouracil—pancreatic cancer	0.00165	0.00575	CbGbCtD
Nilotinib—CYP2C9—Tamoxifen—pancreatic cancer	0.00156	0.00544	CbGbCtD
Nilotinib—ABCB1—Tamoxifen—pancreatic cancer	0.00151	0.00528	CbGbCtD
Nilotinib—CYP2D6—Tamoxifen—pancreatic cancer	0.00143	0.00498	CbGbCtD
Nilotinib—ABCB1—Gemcitabine—pancreatic cancer	0.0013	0.00455	CbGbCtD
Nilotinib—ABCB1—Erlotinib—pancreatic cancer	0.00129	0.00449	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—pancreatic cancer	0.00124	0.00432	CbGbCtD
Nilotinib—CYP2D6—Erlotinib—pancreatic cancer	0.00121	0.00423	CbGbCtD
Nilotinib—ABCB1—Irinotecan—pancreatic cancer	0.00116	0.00406	CbGbCtD
Nilotinib—CYP2C9—Fluorouracil—pancreatic cancer	0.00115	0.00401	CbGbCtD
Nilotinib—CYP3A4—Tamoxifen—pancreatic cancer	0.000907	0.00317	CbGbCtD
Nilotinib—ABCB1—Docetaxel—pancreatic cancer	0.000852	0.00297	CbGbCtD
Nilotinib—ABCB1—Sunitinib—pancreatic cancer	0.000848	0.00296	CbGbCtD
Nilotinib—Ponatinib—SRC—pancreatic cancer	0.000819	0.516	CrCbGaD
Nilotinib—CDC42BPB—islet of Langerhans—pancreatic cancer	0.000796	0.0529	CbGeAlD
Nilotinib—CYP3A4—Erlotinib—pancreatic cancer	0.000772	0.00269	CbGbCtD
Nilotinib—Ponatinib—KDR—pancreatic cancer	0.000769	0.484	CrCbGaD
Nilotinib—MAPK8—islet of Langerhans—pancreatic cancer	0.00072	0.0479	CbGeAlD
Nilotinib—CA9—gall bladder—pancreatic cancer	0.000716	0.0475	CbGeAlD
Nilotinib—CYP3A4—Irinotecan—pancreatic cancer	0.000697	0.00243	CbGbCtD
Nilotinib—ABCB1—Doxorubicin—pancreatic cancer	0.000635	0.00222	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—pancreatic cancer	0.000599	0.00209	CbGbCtD
Nilotinib—PDGFRA—gall bladder—pancreatic cancer	0.000574	0.0381	CbGeAlD
Nilotinib—EPHB2—digestive system—pancreatic cancer	0.000541	0.0359	CbGeAlD
Nilotinib—CYP3A4—Docetaxel—pancreatic cancer	0.000511	0.00178	CbGbCtD
Nilotinib—CYP3A4—Sunitinib—pancreatic cancer	0.000508	0.00177	CbGbCtD
Nilotinib—MAPK8—pancreas—pancreatic cancer	0.000506	0.0336	CbGeAlD
Nilotinib—ABL1—Topotecan—Irinotecan—pancreatic cancer	0.000495	0.424	CbGdCrCtD
Nilotinib—CDC42BPB—digestive system—pancreatic cancer	0.000478	0.0318	CbGeAlD
Nilotinib—CA9—islet of Langerhans—pancreatic cancer	0.000469	0.0312	CbGeAlD
Nilotinib—KIT—gall bladder—pancreatic cancer	0.000458	0.0305	CbGeAlD
Nilotinib—PDGFRB—gall bladder—pancreatic cancer	0.000448	0.0298	CbGeAlD
Nilotinib—EPHB4—islet of Langerhans—pancreatic cancer	0.000434	0.0288	CbGeAlD
Nilotinib—MAPK8—digestive system—pancreatic cancer	0.000432	0.0287	CbGeAlD
Nilotinib—EPHA2—islet of Langerhans—pancreatic cancer	0.000425	0.0283	CbGeAlD
Nilotinib—EPHB6—islet of Langerhans—pancreatic cancer	0.000397	0.0264	CbGeAlD
Nilotinib—CYP3A4—Doxorubicin—pancreatic cancer	0.000381	0.00133	CbGbCtD
Nilotinib—EPHB3—digestive system—pancreatic cancer	0.000357	0.0237	CbGeAlD
Nilotinib—HCK—digestive system—pancreatic cancer	0.000328	0.0218	CbGeAlD
Nilotinib—CA7—digestive system—pancreatic cancer	0.000321	0.0213	CbGeAlD
Nilotinib—EPHB4—pancreas—pancreatic cancer	0.000305	0.0203	CbGeAlD
Nilotinib—EPHA2—pancreas—pancreatic cancer	0.000299	0.0199	CbGeAlD
Nilotinib—PDGFRB—islet of Langerhans—pancreatic cancer	0.000294	0.0195	CbGeAlD
Nilotinib—TEK—pancreas—pancreatic cancer	0.000292	0.0194	CbGeAlD
Nilotinib—CA9—digestive system—pancreatic cancer	0.000282	0.0187	CbGeAlD
Nilotinib—MAPK14—digestive system—pancreatic cancer	0.000275	0.0182	CbGeAlD
Nilotinib—FGR—digestive system—pancreatic cancer	0.000273	0.0182	CbGeAlD
Nilotinib—CA2—gall bladder—pancreatic cancer	0.000272	0.0181	CbGeAlD
Nilotinib—ABL1—islet of Langerhans—pancreatic cancer	0.000262	0.0174	CbGeAlD
Nilotinib—EPHB4—digestive system—pancreatic cancer	0.00026	0.0173	CbGeAlD
Nilotinib—EPHA2—digestive system—pancreatic cancer	0.000255	0.017	CbGeAlD
Nilotinib—PDGFRA—digestive system—pancreatic cancer	0.000226	0.015	CbGeAlD
Nilotinib—UGT1A1—digestive system—pancreatic cancer	0.000215	0.0143	CbGeAlD
Nilotinib—CA4—islet of Langerhans—pancreatic cancer	0.000215	0.0143	CbGeAlD
Nilotinib—KIT—pancreas—pancreatic cancer	0.000211	0.014	CbGeAlD
Nilotinib—CA12—digestive system—pancreatic cancer	0.000208	0.0138	CbGeAlD
Nilotinib—PDGFRB—pancreas—pancreatic cancer	0.000206	0.0137	CbGeAlD
Nilotinib—CSF1R—digestive system—pancreatic cancer	0.000199	0.0132	CbGeAlD
Nilotinib—CA1—pancreas—pancreatic cancer	0.000193	0.0128	CbGeAlD
Nilotinib—ABL1—pancreas—pancreatic cancer	0.000184	0.0122	CbGeAlD
Nilotinib—KIT—digestive system—pancreatic cancer	0.00018	0.012	CbGeAlD
Nilotinib—CA2—islet of Langerhans—pancreatic cancer	0.000178	0.0118	CbGeAlD
Nilotinib—PDGFRB—digestive system—pancreatic cancer	0.000176	0.0117	CbGeAlD
Nilotinib—CA1—digestive system—pancreatic cancer	0.000165	0.011	CbGeAlD
Nilotinib—ABL1—digestive system—pancreatic cancer	0.000157	0.0104	CbGeAlD
Nilotinib—CA4—digestive system—pancreatic cancer	0.000129	0.00857	CbGeAlD
Nilotinib—CA2—pancreas—pancreatic cancer	0.000125	0.00832	CbGeAlD
Nilotinib—ABL1—Daunorubicin—Epirubicin—pancreatic cancer	0.000116	0.0997	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Epirubicin—pancreatic cancer	0.000116	0.0997	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—pancreatic cancer	0.000116	0.0997	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—pancreatic cancer	0.000108	0.0922	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Doxorubicin—pancreatic cancer	0.000108	0.0922	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—pancreatic cancer	0.000108	0.0922	CbGdCrCtD
Nilotinib—CA2—digestive system—pancreatic cancer	0.000107	0.00711	CbGeAlD
Nilotinib—CYP2B6—digestive system—pancreatic cancer	9.14e-05	0.00607	CbGeAlD
Nilotinib—CYP2C9—digestive system—pancreatic cancer	9.05e-05	0.00601	CbGeAlD
Nilotinib—ABCB1—islet of Langerhans—pancreatic cancer	8.14e-05	0.00541	CbGeAlD
Nilotinib—CYP3A4—digestive system—pancreatic cancer	6.9e-05	0.00459	CbGeAlD
Nilotinib—CYP2D6—digestive system—pancreatic cancer	6.79e-05	0.00451	CbGeAlD
Nilotinib—ABCB1—pancreas—pancreatic cancer	5.72e-05	0.0038	CbGeAlD
Nilotinib—ABCB1—digestive system—pancreatic cancer	4.88e-05	0.00325	CbGeAlD
Nilotinib—Dysuria—Doxorubicin—pancreatic cancer	2.23e-05	0.000302	CcSEcCtD
Nilotinib—Neutropenia—Doxorubicin—pancreatic cancer	2.23e-05	0.000302	CcSEcCtD
Nilotinib—Hypersensitivity—Fluorouracil—pancreatic cancer	2.22e-05	0.000301	CcSEcCtD
Nilotinib—Dry mouth—Docetaxel—pancreatic cancer	2.22e-05	0.0003	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	2.22e-05	0.0003	CcSEcCtD
Nilotinib—Pollakiuria—Doxorubicin—pancreatic cancer	2.21e-05	0.000299	CcSEcCtD
Nilotinib—Asthenia—Gemcitabine—pancreatic cancer	2.2e-05	0.000298	CcSEcCtD
Nilotinib—Haematuria—Epirubicin—pancreatic cancer	2.19e-05	0.000297	CcSEcCtD
Nilotinib—Confusional state—Docetaxel—pancreatic cancer	2.19e-05	0.000297	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—pancreatic cancer	2.18e-05	0.000295	CcSEcCtD
Nilotinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	2.18e-05	0.000295	CcSEcCtD
Nilotinib—Oedema—Docetaxel—pancreatic cancer	2.17e-05	0.000295	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—pancreatic cancer	2.17e-05	0.000294	CcSEcCtD
Nilotinib—Epistaxis—Epirubicin—pancreatic cancer	2.17e-05	0.000294	CcSEcCtD
Nilotinib—Pruritus—Gemcitabine—pancreatic cancer	2.17e-05	0.000294	CcSEcCtD
Nilotinib—Infection—Docetaxel—pancreatic cancer	2.16e-05	0.000293	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—pancreatic cancer	2.16e-05	0.000292	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—pancreatic cancer	2.15e-05	0.000292	CcSEcCtD
Nilotinib—Diarrhoea—Irinotecan—pancreatic cancer	2.15e-05	0.000292	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—pancreatic cancer	2.14e-05	0.00029	CcSEcCtD
Nilotinib—Shock—Docetaxel—pancreatic cancer	2.14e-05	0.00029	CcSEcCtD
Nilotinib—Nervous system disorder—Docetaxel—pancreatic cancer	2.13e-05	0.000289	CcSEcCtD
Nilotinib—Pruritus—Fluorouracil—pancreatic cancer	2.13e-05	0.000289	CcSEcCtD
Nilotinib—Thrombocytopenia—Docetaxel—pancreatic cancer	2.13e-05	0.000288	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—pancreatic cancer	2.13e-05	0.000288	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—pancreatic cancer	2.13e-05	0.000288	CcSEcCtD
Nilotinib—Tachycardia—Docetaxel—pancreatic cancer	2.12e-05	0.000287	CcSEcCtD
Nilotinib—Skin disorder—Docetaxel—pancreatic cancer	2.11e-05	0.000286	CcSEcCtD
Nilotinib—Bradycardia—Epirubicin—pancreatic cancer	2.1e-05	0.000285	CcSEcCtD
Nilotinib—Diarrhoea—Gemcitabine—pancreatic cancer	2.1e-05	0.000284	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—pancreatic cancer	2.09e-05	0.000283	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	2.09e-05	0.000283	CcSEcCtD
Nilotinib—Dizziness—Irinotecan—pancreatic cancer	2.08e-05	0.000282	CcSEcCtD
Nilotinib—Haemoglobin—Epirubicin—pancreatic cancer	2.08e-05	0.000281	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—pancreatic cancer	2.07e-05	0.000281	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—pancreatic cancer	2.07e-05	0.000281	CcSEcCtD
Nilotinib—Anorexia—Docetaxel—pancreatic cancer	2.07e-05	0.000281	CcSEcCtD
Nilotinib—Rhinitis—Epirubicin—pancreatic cancer	2.07e-05	0.00028	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—pancreatic cancer	2.07e-05	0.00028	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—pancreatic cancer	2.07e-05	0.00028	CcSEcCtD
Nilotinib—Haemorrhage—Epirubicin—pancreatic cancer	2.06e-05	0.00028	CcSEcCtD
Nilotinib—Hepatitis—Epirubicin—pancreatic cancer	2.06e-05	0.00028	CcSEcCtD
Nilotinib—Diarrhoea—Fluorouracil—pancreatic cancer	2.06e-05	0.000279	CcSEcCtD
Nilotinib—Hypoaesthesia—Epirubicin—pancreatic cancer	2.05e-05	0.000278	CcSEcCtD
Nilotinib—Pharyngitis—Epirubicin—pancreatic cancer	2.05e-05	0.000278	CcSEcCtD
Nilotinib—Urinary tract disorder—Epirubicin—pancreatic cancer	2.04e-05	0.000276	CcSEcCtD
Nilotinib—Oedema peripheral—Epirubicin—pancreatic cancer	2.03e-05	0.000275	CcSEcCtD
Nilotinib—Hypotension—Docetaxel—pancreatic cancer	2.03e-05	0.000275	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—pancreatic cancer	2.03e-05	0.000275	CcSEcCtD
Nilotinib—Connective tissue disorder—Epirubicin—pancreatic cancer	2.03e-05	0.000275	CcSEcCtD
Nilotinib—Urethral disorder—Epirubicin—pancreatic cancer	2.02e-05	0.000274	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	2.01e-05	0.000273	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—pancreatic cancer	2.01e-05	0.000272	CcSEcCtD
Nilotinib—Vomiting—Irinotecan—pancreatic cancer	2e-05	0.000271	CcSEcCtD
Nilotinib—Dizziness—Fluorouracil—pancreatic cancer	1.99e-05	0.00027	CcSEcCtD
Nilotinib—Visual impairment—Epirubicin—pancreatic cancer	1.99e-05	0.000269	CcSEcCtD
Nilotinib—Rash—Irinotecan—pancreatic cancer	1.98e-05	0.000269	CcSEcCtD
Nilotinib—Dermatitis—Irinotecan—pancreatic cancer	1.98e-05	0.000268	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	1.98e-05	0.000268	CcSEcCtD
Nilotinib—Headache—Irinotecan—pancreatic cancer	1.97e-05	0.000267	CcSEcCtD
Nilotinib—Insomnia—Docetaxel—pancreatic cancer	1.97e-05	0.000266	CcSEcCtD
Nilotinib—Paraesthesia—Docetaxel—pancreatic cancer	1.95e-05	0.000264	CcSEcCtD
Nilotinib—Erythema multiforme—Epirubicin—pancreatic cancer	1.95e-05	0.000264	CcSEcCtD
Nilotinib—Vomiting—Gemcitabine—pancreatic cancer	1.95e-05	0.000264	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—pancreatic cancer	1.95e-05	0.000263	CcSEcCtD
Nilotinib—Dyspnoea—Docetaxel—pancreatic cancer	1.94e-05	0.000263	CcSEcCtD
Nilotinib—Rash—Gemcitabine—pancreatic cancer	1.93e-05	0.000262	CcSEcCtD
Nilotinib—Dermatitis—Gemcitabine—pancreatic cancer	1.93e-05	0.000261	CcSEcCtD
Nilotinib—Eye disorder—Epirubicin—pancreatic cancer	1.93e-05	0.000261	CcSEcCtD
Nilotinib—Tinnitus—Epirubicin—pancreatic cancer	1.93e-05	0.000261	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—pancreatic cancer	1.92e-05	0.00026	CcSEcCtD
Nilotinib—Headache—Gemcitabine—pancreatic cancer	1.92e-05	0.00026	CcSEcCtD
Nilotinib—Flushing—Epirubicin—pancreatic cancer	1.92e-05	0.00026	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—pancreatic cancer	1.92e-05	0.00026	CcSEcCtD
Nilotinib—Vomiting—Fluorouracil—pancreatic cancer	1.92e-05	0.000259	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—pancreatic cancer	1.92e-05	0.000259	CcSEcCtD
Nilotinib—Dyspepsia—Docetaxel—pancreatic cancer	1.91e-05	0.000259	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—pancreatic cancer	1.91e-05	0.000259	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—pancreatic cancer	1.91e-05	0.000259	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—pancreatic cancer	1.9e-05	0.000257	CcSEcCtD
Nilotinib—Rash—Fluorouracil—pancreatic cancer	1.9e-05	0.000257	CcSEcCtD
Nilotinib—Dermatitis—Fluorouracil—pancreatic cancer	1.9e-05	0.000257	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—pancreatic cancer	1.9e-05	0.000257	CcSEcCtD
Nilotinib—Decreased appetite—Docetaxel—pancreatic cancer	1.89e-05	0.000256	CcSEcCtD
Nilotinib—Headache—Fluorouracil—pancreatic cancer	1.89e-05	0.000256	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	1.89e-05	0.000256	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—pancreatic cancer	1.88e-05	0.000255	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	1.88e-05	0.000254	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	1.88e-05	0.000254	CcSEcCtD
Nilotinib—Fatigue—Docetaxel—pancreatic cancer	1.88e-05	0.000254	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—pancreatic cancer	1.87e-05	0.000254	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—pancreatic cancer	1.87e-05	0.000254	CcSEcCtD
Nilotinib—Nausea—Irinotecan—pancreatic cancer	1.87e-05	0.000253	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—pancreatic cancer	1.87e-05	0.000253	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—pancreatic cancer	1.86e-05	0.000252	CcSEcCtD
Nilotinib—Pain—Docetaxel—pancreatic cancer	1.86e-05	0.000252	CcSEcCtD
Nilotinib—Constipation—Docetaxel—pancreatic cancer	1.86e-05	0.000252	CcSEcCtD
Nilotinib—Chills—Epirubicin—pancreatic cancer	1.85e-05	0.000251	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—pancreatic cancer	1.84e-05	0.00025	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—pancreatic cancer	1.84e-05	0.000249	CcSEcCtD
Nilotinib—Alopecia—Epirubicin—pancreatic cancer	1.82e-05	0.000247	CcSEcCtD
Nilotinib—Nausea—Gemcitabine—pancreatic cancer	1.82e-05	0.000247	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—pancreatic cancer	1.81e-05	0.000245	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—pancreatic cancer	1.81e-05	0.000245	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—pancreatic cancer	1.8e-05	0.000243	CcSEcCtD
Nilotinib—Erythema—Epirubicin—pancreatic cancer	1.8e-05	0.000243	CcSEcCtD
Nilotinib—Feeling abnormal—Docetaxel—pancreatic cancer	1.79e-05	0.000243	CcSEcCtD
Nilotinib—Nausea—Fluorouracil—pancreatic cancer	1.79e-05	0.000242	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—pancreatic cancer	1.79e-05	0.000242	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—pancreatic cancer	1.78e-05	0.000241	CcSEcCtD
Nilotinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	1.78e-05	0.000241	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—pancreatic cancer	1.77e-05	0.00024	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—pancreatic cancer	1.77e-05	0.00024	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—pancreatic cancer	1.77e-05	0.00024	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—pancreatic cancer	1.76e-05	0.000238	CcSEcCtD
Nilotinib—Back pain—Epirubicin—pancreatic cancer	1.74e-05	0.000235	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—pancreatic cancer	1.73e-05	0.000235	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—pancreatic cancer	1.73e-05	0.000234	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—pancreatic cancer	1.73e-05	0.000234	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	1.72e-05	0.000233	CcSEcCtD
Nilotinib—Abdominal pain—Docetaxel—pancreatic cancer	1.72e-05	0.000233	CcSEcCtD
Nilotinib—Body temperature increased—Docetaxel—pancreatic cancer	1.72e-05	0.000233	CcSEcCtD
Nilotinib—Chills—Doxorubicin—pancreatic cancer	1.71e-05	0.000232	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—pancreatic cancer	1.71e-05	0.000231	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—pancreatic cancer	1.69e-05	0.000229	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—pancreatic cancer	1.69e-05	0.000229	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—pancreatic cancer	1.67e-05	0.000227	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—pancreatic cancer	1.67e-05	0.000226	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—pancreatic cancer	1.66e-05	0.000225	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—pancreatic cancer	1.66e-05	0.000225	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—pancreatic cancer	1.66e-05	0.000225	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—pancreatic cancer	1.64e-05	0.000222	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—pancreatic cancer	1.63e-05	0.000221	CcSEcCtD
Nilotinib—Malaise—Epirubicin—pancreatic cancer	1.62e-05	0.00022	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—pancreatic cancer	1.61e-05	0.000219	CcSEcCtD
Nilotinib—Syncope—Epirubicin—pancreatic cancer	1.61e-05	0.000218	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—pancreatic cancer	1.61e-05	0.000218	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—pancreatic cancer	1.61e-05	0.000218	CcSEcCtD
Nilotinib—Hypersensitivity—Docetaxel—pancreatic cancer	1.6e-05	0.000217	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—pancreatic cancer	1.6e-05	0.000217	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—pancreatic cancer	1.59e-05	0.000215	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—pancreatic cancer	1.58e-05	0.000214	CcSEcCtD
Nilotinib—Cough—Epirubicin—pancreatic cancer	1.57e-05	0.000212	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—pancreatic cancer	1.57e-05	0.000212	CcSEcCtD
Nilotinib—Asthenia—Docetaxel—pancreatic cancer	1.56e-05	0.000211	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—pancreatic cancer	1.55e-05	0.00021	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—pancreatic cancer	1.54e-05	0.000209	CcSEcCtD
Nilotinib—Pruritus—Docetaxel—pancreatic cancer	1.54e-05	0.000208	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—pancreatic cancer	1.54e-05	0.000208	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—pancreatic cancer	1.53e-05	0.000207	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—pancreatic cancer	1.53e-05	0.000207	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—pancreatic cancer	1.53e-05	0.000207	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—pancreatic cancer	1.53e-05	0.000207	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	1.52e-05	0.000206	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—pancreatic cancer	1.51e-05	0.000205	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—pancreatic cancer	1.5e-05	0.000203	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—pancreatic cancer	1.5e-05	0.000203	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—pancreatic cancer	1.49e-05	0.000202	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—pancreatic cancer	1.49e-05	0.000202	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—pancreatic cancer	1.49e-05	0.000202	CcSEcCtD
Nilotinib—Diarrhoea—Docetaxel—pancreatic cancer	1.49e-05	0.000202	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—pancreatic cancer	1.48e-05	0.0002	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—pancreatic cancer	1.47e-05	0.000199	CcSEcCtD
Nilotinib—Oedema—Epirubicin—pancreatic cancer	1.47e-05	0.000199	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—pancreatic cancer	1.46e-05	0.000198	CcSEcCtD
Nilotinib—Infection—Epirubicin—pancreatic cancer	1.46e-05	0.000197	CcSEcCtD
Nilotinib—Cough—Doxorubicin—pancreatic cancer	1.45e-05	0.000197	CcSEcCtD
Nilotinib—Shock—Epirubicin—pancreatic cancer	1.44e-05	0.000195	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—pancreatic cancer	1.44e-05	0.000195	CcSEcCtD
Nilotinib—Dizziness—Docetaxel—pancreatic cancer	1.44e-05	0.000195	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—pancreatic cancer	1.44e-05	0.000195	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—pancreatic cancer	1.44e-05	0.000194	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—pancreatic cancer	1.43e-05	0.000194	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—pancreatic cancer	1.42e-05	0.000193	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—pancreatic cancer	1.42e-05	0.000192	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—pancreatic cancer	1.42e-05	0.000192	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—pancreatic cancer	1.42e-05	0.000192	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—pancreatic cancer	1.42e-05	0.000192	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—pancreatic cancer	1.41e-05	0.000191	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	1.41e-05	0.00019	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—pancreatic cancer	1.4e-05	0.000189	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—pancreatic cancer	1.4e-05	0.000189	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—pancreatic cancer	1.38e-05	0.000188	CcSEcCtD
Nilotinib—Vomiting—Docetaxel—pancreatic cancer	1.38e-05	0.000187	CcSEcCtD
Nilotinib—Rash—Docetaxel—pancreatic cancer	1.37e-05	0.000186	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—pancreatic cancer	1.37e-05	0.000186	CcSEcCtD
Nilotinib—Dermatitis—Docetaxel—pancreatic cancer	1.37e-05	0.000186	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—pancreatic cancer	1.37e-05	0.000185	CcSEcCtD
Nilotinib—Headache—Docetaxel—pancreatic cancer	1.36e-05	0.000185	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—pancreatic cancer	1.36e-05	0.000184	CcSEcCtD
Nilotinib—Infection—Doxorubicin—pancreatic cancer	1.35e-05	0.000183	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	1.34e-05	0.000181	CcSEcCtD
Nilotinib—Shock—Doxorubicin—pancreatic cancer	1.34e-05	0.000181	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—pancreatic cancer	1.33e-05	0.00018	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	1.33e-05	0.00018	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—pancreatic cancer	1.33e-05	0.00018	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—pancreatic cancer	1.32e-05	0.000179	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—pancreatic cancer	1.32e-05	0.000179	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—pancreatic cancer	1.32e-05	0.000178	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—pancreatic cancer	1.31e-05	0.000178	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—pancreatic cancer	1.31e-05	0.000177	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—pancreatic cancer	1.29e-05	0.000175	CcSEcCtD
Nilotinib—Nausea—Docetaxel—pancreatic cancer	1.29e-05	0.000175	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—pancreatic cancer	1.29e-05	0.000175	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—pancreatic cancer	1.28e-05	0.000173	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—pancreatic cancer	1.27e-05	0.000172	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.27e-05	0.000172	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—pancreatic cancer	1.26e-05	0.000171	CcSEcCtD
Nilotinib—Constipation—Epirubicin—pancreatic cancer	1.25e-05	0.00017	CcSEcCtD
Nilotinib—Pain—Epirubicin—pancreatic cancer	1.25e-05	0.00017	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	1.24e-05	0.000167	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—pancreatic cancer	1.23e-05	0.000166	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—pancreatic cancer	1.22e-05	0.000165	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—pancreatic cancer	1.21e-05	0.000164	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—pancreatic cancer	1.21e-05	0.000164	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.2e-05	0.000162	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—pancreatic cancer	1.19e-05	0.000162	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—pancreatic cancer	1.18e-05	0.00016	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.17e-05	0.000159	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—pancreatic cancer	1.17e-05	0.000158	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—pancreatic cancer	1.17e-05	0.000158	CcSEcCtD
Nilotinib—Pain—Doxorubicin—pancreatic cancer	1.16e-05	0.000157	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—pancreatic cancer	1.16e-05	0.000157	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—pancreatic cancer	1.16e-05	0.000157	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—pancreatic cancer	1.16e-05	0.000157	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—pancreatic cancer	1.12e-05	0.000151	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.11e-05	0.00015	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—pancreatic cancer	1.08e-05	0.000146	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—pancreatic cancer	1.08e-05	0.000146	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—pancreatic cancer	1.07e-05	0.000145	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—pancreatic cancer	1.07e-05	0.000145	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—pancreatic cancer	1.05e-05	0.000143	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—pancreatic cancer	1.04e-05	0.000141	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—pancreatic cancer	1e-05	0.000136	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—pancreatic cancer	1e-05	0.000135	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—pancreatic cancer	9.74e-06	0.000132	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—pancreatic cancer	9.7e-06	0.000131	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—pancreatic cancer	9.6e-06	0.00013	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—pancreatic cancer	9.33e-06	0.000126	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—pancreatic cancer	9.29e-06	0.000126	CcSEcCtD
Nilotinib—Rash—Epirubicin—pancreatic cancer	9.25e-06	0.000125	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—pancreatic cancer	9.24e-06	0.000125	CcSEcCtD
Nilotinib—Headache—Epirubicin—pancreatic cancer	9.19e-06	0.000124	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—pancreatic cancer	8.98e-06	0.000122	CcSEcCtD
Nilotinib—Nausea—Epirubicin—pancreatic cancer	8.71e-06	0.000118	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—pancreatic cancer	8.63e-06	0.000117	CcSEcCtD
Nilotinib—Rash—Doxorubicin—pancreatic cancer	8.56e-06	0.000116	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—pancreatic cancer	8.55e-06	0.000116	CcSEcCtD
Nilotinib—Headache—Doxorubicin—pancreatic cancer	8.5e-06	0.000115	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—pancreatic cancer	8.06e-06	0.000109	CcSEcCtD
Nilotinib—BRAF—Signaling Pathways—NRAS—pancreatic cancer	7.52e-07	1.07e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTEN—pancreatic cancer	7.5e-07	1.07e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—pancreatic cancer	7.47e-07	1.06e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—pancreatic cancer	7.45e-07	1.06e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	7.44e-07	1.06e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—STK11—pancreatic cancer	7.42e-07	1.06e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CB—pancreatic cancer	7.42e-07	1.06e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—STK11—pancreatic cancer	7.35e-07	1.05e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—pancreatic cancer	7.33e-07	1.04e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—DPYD—pancreatic cancer	7.32e-07	1.04e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—pancreatic cancer	7.32e-07	1.04e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—pancreatic cancer	7.31e-07	1.04e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—pancreatic cancer	7.29e-07	1.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—pancreatic cancer	7.28e-07	1.04e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—pancreatic cancer	7.27e-07	1.03e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTEN—pancreatic cancer	7.27e-07	1.03e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NRAS—pancreatic cancer	7.25e-07	1.03e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—pancreatic cancer	7.22e-07	1.03e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—pancreatic cancer	7.18e-07	1.02e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTEN—pancreatic cancer	7.17e-07	1.02e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—pancreatic cancer	7.17e-07	1.02e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—pancreatic cancer	7.15e-07	1.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—pancreatic cancer	7.14e-07	1.02e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—pancreatic cancer	7.13e-07	1.01e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SRC—pancreatic cancer	7.12e-07	1.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—pancreatic cancer	7.07e-07	1.01e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—pancreatic cancer	7.06e-07	1e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	7.04e-07	1e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CB—pancreatic cancer	7.03e-07	1e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—pancreatic cancer	7.01e-07	9.98e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—pancreatic cancer	6.99e-07	9.96e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—pancreatic cancer	6.99e-07	9.95e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—pancreatic cancer	6.98e-07	9.94e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CD—pancreatic cancer	6.97e-07	9.93e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—pancreatic cancer	6.97e-07	9.93e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—pancreatic cancer	6.97e-07	9.92e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—pancreatic cancer	6.96e-07	9.91e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—SRC—pancreatic cancer	6.96e-07	9.91e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	6.95e-07	9.89e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—pancreatic cancer	6.94e-07	9.88e-06	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—pancreatic cancer	6.94e-07	9.88e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—pancreatic cancer	6.93e-07	9.87e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—pancreatic cancer	6.93e-07	9.87e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—pancreatic cancer	6.92e-07	9.85e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.9e-07	9.83e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—pancreatic cancer	6.86e-07	9.77e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—pancreatic cancer	6.85e-07	9.76e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—pancreatic cancer	6.85e-07	9.75e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—pancreatic cancer	6.84e-07	9.74e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—pancreatic cancer	6.82e-07	9.71e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—pancreatic cancer	6.78e-07	9.66e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—pancreatic cancer	6.77e-07	9.64e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TYMS—pancreatic cancer	6.77e-07	9.64e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—pancreatic cancer	6.76e-07	9.62e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SRC—pancreatic cancer	6.74e-07	9.59e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	6.74e-07	9.59e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—pancreatic cancer	6.72e-07	9.56e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—pancreatic cancer	6.71e-07	9.55e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—pancreatic cancer	6.69e-07	9.53e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—pancreatic cancer	6.64e-07	9.45e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—pancreatic cancer	6.63e-07	9.44e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—pancreatic cancer	6.63e-07	9.44e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—pancreatic cancer	6.61e-07	9.41e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—pancreatic cancer	6.6e-07	9.4e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—pancreatic cancer	6.59e-07	9.39e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—pancreatic cancer	6.58e-07	9.38e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—pancreatic cancer	6.58e-07	9.36e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—pancreatic cancer	6.56e-07	9.34e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—pancreatic cancer	6.55e-07	9.32e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—pancreatic cancer	6.54e-07	9.31e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—pancreatic cancer	6.5e-07	9.26e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—pancreatic cancer	6.5e-07	9.25e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—pancreatic cancer	6.48e-07	9.23e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—pancreatic cancer	6.48e-07	9.22e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—pancreatic cancer	6.48e-07	9.22e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—pancreatic cancer	6.47e-07	9.21e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—pancreatic cancer	6.47e-07	9.21e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—pancreatic cancer	6.45e-07	9.18e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—pancreatic cancer	6.44e-07	9.17e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—pancreatic cancer	6.41e-07	9.13e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—pancreatic cancer	6.38e-07	9.08e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—pancreatic cancer	6.38e-07	9.08e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—pancreatic cancer	6.36e-07	9.06e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—pancreatic cancer	6.33e-07	9.01e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—pancreatic cancer	6.32e-07	9e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—pancreatic cancer	6.32e-07	8.99e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—pancreatic cancer	6.29e-07	8.96e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—pancreatic cancer	6.24e-07	8.88e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—pancreatic cancer	6.24e-07	8.88e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—pancreatic cancer	6.23e-07	8.88e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—pancreatic cancer	6.23e-07	8.88e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—pancreatic cancer	6.22e-07	8.86e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—pancreatic cancer	6.16e-07	8.77e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—pancreatic cancer	6.13e-07	8.73e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—pancreatic cancer	6.11e-07	8.7e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—pancreatic cancer	6.1e-07	8.69e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—pancreatic cancer	6.1e-07	8.68e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—pancreatic cancer	6.09e-07	8.67e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CB—pancreatic cancer	6.08e-07	8.66e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—pancreatic cancer	6.08e-07	8.65e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SRC—pancreatic cancer	6.07e-07	8.64e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—pancreatic cancer	6.04e-07	8.6e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—pancreatic cancer	6.02e-07	8.58e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—pancreatic cancer	6.01e-07	8.55e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.98e-07	8.52e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—pancreatic cancer	5.98e-07	8.51e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—pancreatic cancer	5.95e-07	8.47e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SRC—pancreatic cancer	5.94e-07	8.46e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	5.92e-07	8.43e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—pancreatic cancer	5.91e-07	8.42e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—pancreatic cancer	5.91e-07	8.41e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—pancreatic cancer	5.89e-07	8.39e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—pancreatic cancer	5.85e-07	8.34e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—pancreatic cancer	5.85e-07	8.34e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—pancreatic cancer	5.84e-07	8.32e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—pancreatic cancer	5.84e-07	8.32e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—pancreatic cancer	5.83e-07	8.31e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—pancreatic cancer	5.81e-07	8.27e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—pancreatic cancer	5.79e-07	8.24e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—pancreatic cancer	5.76e-07	8.2e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—pancreatic cancer	5.76e-07	8.19e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—pancreatic cancer	5.73e-07	8.16e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—pancreatic cancer	5.73e-07	8.16e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—pancreatic cancer	5.72e-07	8.14e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—pancreatic cancer	5.71e-07	8.13e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	5.7e-07	8.12e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—pancreatic cancer	5.69e-07	8.1e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SRC—pancreatic cancer	5.63e-07	8.02e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—pancreatic cancer	5.59e-07	7.96e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—pancreatic cancer	5.58e-07	7.94e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—pancreatic cancer	5.56e-07	7.91e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—pancreatic cancer	5.51e-07	7.84e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—pancreatic cancer	5.51e-07	7.84e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—pancreatic cancer	5.5e-07	7.84e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—pancreatic cancer	5.49e-07	7.81e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—pancreatic cancer	5.44e-07	7.75e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—pancreatic cancer	5.44e-07	7.75e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—pancreatic cancer	5.43e-07	7.74e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—pancreatic cancer	5.43e-07	7.73e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—pancreatic cancer	5.42e-07	7.72e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—pancreatic cancer	5.42e-07	7.71e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—pancreatic cancer	5.41e-07	7.71e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—pancreatic cancer	5.39e-07	7.67e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—pancreatic cancer	5.39e-07	7.67e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—pancreatic cancer	5.39e-07	7.67e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD44—pancreatic cancer	5.38e-07	7.66e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—pancreatic cancer	5.33e-07	7.58e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—pancreatic cancer	5.32e-07	7.58e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—pancreatic cancer	5.31e-07	7.57e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—pancreatic cancer	5.3e-07	7.55e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—pancreatic cancer	5.29e-07	7.54e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—pancreatic cancer	5.28e-07	7.52e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—pancreatic cancer	5.25e-07	7.48e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—pancreatic cancer	5.24e-07	7.46e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—pancreatic cancer	5.21e-07	7.42e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—pancreatic cancer	5.19e-07	7.39e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	5.16e-07	7.35e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCG—pancreatic cancer	5.16e-07	7.34e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—pancreatic cancer	5.14e-07	7.32e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—pancreatic cancer	5.13e-07	7.3e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—pancreatic cancer	5.12e-07	7.28e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—pancreatic cancer	5.06e-07	7.21e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—pancreatic cancer	5.05e-07	7.19e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—pancreatic cancer	5.04e-07	7.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—pancreatic cancer	5.03e-07	7.16e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	5.01e-07	7.14e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—pancreatic cancer	5.01e-07	7.13e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	4.97e-07	7.08e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—pancreatic cancer	4.96e-07	7.06e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—pancreatic cancer	4.94e-07	7.03e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—pancreatic cancer	4.92e-07	7.01e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—pancreatic cancer	4.91e-07	6.99e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—pancreatic cancer	4.9e-07	6.97e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SRC—pancreatic cancer	4.87e-07	6.94e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.87e-07	6.93e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—pancreatic cancer	4.86e-07	6.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—STK11—pancreatic cancer	4.85e-07	6.91e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—pancreatic cancer	4.8e-07	6.83e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—pancreatic cancer	4.74e-07	6.76e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—pancreatic cancer	4.74e-07	6.75e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—pancreatic cancer	4.7e-07	6.69e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—pancreatic cancer	4.69e-07	6.67e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.68e-07	6.67e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—pancreatic cancer	4.68e-07	6.67e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—pancreatic cancer	4.67e-07	6.64e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	4.64e-07	6.61e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—pancreatic cancer	4.62e-07	6.58e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—pancreatic cancer	4.52e-07	6.44e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—pancreatic cancer	4.52e-07	6.44e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—pancreatic cancer	4.48e-07	6.38e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—pancreatic cancer	4.47e-07	6.36e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—pancreatic cancer	4.46e-07	6.35e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—pancreatic cancer	4.42e-07	6.3e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—pancreatic cancer	4.37e-07	6.23e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	4.37e-07	6.22e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.37e-07	6.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—pancreatic cancer	4.37e-07	6.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—pancreatic cancer	4.35e-07	6.2e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	4.33e-07	6.17e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—pancreatic cancer	4.32e-07	6.16e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	4.29e-07	6.11e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—pancreatic cancer	4.29e-07	6.1e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—pancreatic cancer	4.27e-07	6.08e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—pancreatic cancer	4.27e-07	6.08e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—pancreatic cancer	4.19e-07	5.96e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—pancreatic cancer	4.18e-07	5.96e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.17e-07	5.94e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—pancreatic cancer	4.15e-07	5.9e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—pancreatic cancer	4.13e-07	5.89e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	4.12e-07	5.86e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	4.08e-07	5.81e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—pancreatic cancer	4.03e-07	5.74e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—pancreatic cancer	3.97e-07	5.65e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.81e-07	5.42e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—pancreatic cancer	3.78e-07	5.38e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.77e-07	5.37e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—pancreatic cancer	3.77e-07	5.37e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—pancreatic cancer	3.71e-07	5.28e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—pancreatic cancer	3.69e-07	5.26e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.59e-07	5.11e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—pancreatic cancer	3.59e-07	5.1e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	3.56e-07	5.07e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.56e-07	5.06e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—pancreatic cancer	3.52e-07	5.02e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—pancreatic cancer	3.51e-07	4.99e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—pancreatic cancer	3.5e-07	4.99e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—pancreatic cancer	3.43e-07	4.88e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—pancreatic cancer	3.39e-07	4.83e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—pancreatic cancer	3.29e-07	4.69e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	3.15e-07	4.48e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.1e-07	4.42e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—pancreatic cancer	3.07e-07	4.38e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.06e-07	4.36e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—pancreatic cancer	3.03e-07	4.31e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.95e-07	4.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.69e-07	3.83e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.66e-07	3.79e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—pancreatic cancer	2.57e-07	3.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.35e-07	3.34e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.32e-07	3.31e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.32e-07	3.31e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.19e-07	3.11e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—pancreatic cancer	2.18e-07	3.1e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.17e-07	3.09e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.03e-07	2.89e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—pancreatic cancer	1.9e-07	2.7e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.79e-07	2.54e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.77e-07	2.52e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.43e-07	2.04e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.17e-07	1.66e-06	CbGpPWpGaD
